It’s been just over a year since the EPO’s Enlarged Board of Appeal (EBA) handed down its landmark decision in G2/21, setting out a brand-new test for determining the admissibility of post-filed data and replacing the previously used catchword “plausibility”. The use of supporting data is especially important in the life sciences sector, with applicants routinely having to balance the race to file with the availability of the experimental evidence to support their patent applications.
So, what has been the impact of this new test? Our G2/21 experts Tom Leonard, Bethany Myers and Joseph Etherington, who you may remember from our “Fast Response” webinar on this topic last year, are back. They will provide an update on how this decision has been applied (or not!) around Europe.
This webinar will cover:
-
A refresher on the EBA’s new test for admitting post-filed data into proceedings;
-
A digest of key recent case law where G2/21 has been considered and implemented, at both the EPO and national courts; and
-
What practical steps patent applicants and opponents can take in view of how G2/21 is being implemented in practice, to maximise their chances of success in Europe.
We hope you can join!